Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup Edited by Gargi Mukherjee

https://www.medscape.com/viewarticle/quizartinib-benefit-aml-limited-flt3-mutated-subgroup-2026a1000oqq?src= Adding quizartinib after intensive chemotherapy was associated with improved 5-year overall survival among older patients with FLT3-mutated AML in subgroup analyses, but not in the overall trial population, where quizartinib was associated with increased nonrelapse mortality. No additional benefit was seen with extended quizartinib maintenance therapy in the overall population or the wild-type FLT3 AML group.